Advances in immunotherapy modalities for atherosclerosis

Qingwen Meng; Huajiang Liu; Jinteng Liu; Yangyang Pang; Qibing Liu

doi:10.3389/fphar.2022.1079185

Advances in immunotherapy modalities for atherosclerosis

Front Pharmacol. 2023 Jan 10:13:1079185. doi: 10.3389/fphar.2022.1079185. eCollection 2022.

Authors

Qingwen Meng^{1

2

3}, Huajiang Liu², Jinteng Liu⁴, Yangyang Pang⁴, Qibing Liu^{1

4}

Affiliations

¹ Department of Pharmacy, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
² Deparment of Cardiovascular, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
³ Hainan Provincial Key Laboratory of Tropical Brain Research and Transformation, Hainan Medical University, Haikou, China.
⁴ School of Basic Medicine and Life Sciences, Hainan Medical University, Haikou, China.

Abstract

Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Atherosclerosis is the pathological basis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is now understood to be a long-term immune-mediated inflammatory condition brought on by a complicated chain of factors, including endothelial dysfunction, lipid deposits in the artery wall, and monocyte-derived macrophage infiltration, in which both innate immunity and adaptive immunity play an indispensable role. Recent studies have shown that atherosclerosis can be alleviated by inducing a protective immune response through certain auto-antigens or exogenous antigens. Some clinical trials have also demonstrated that atherosclerotic is associated with the presence of immune cells and immune factors in the body. Therefore, immunotherapy is expected to be a new preventive and curative measure for atherosclerosis. In this review, we provide a summary overview of recent progress in the research of immune mechanisms of atherosclerosis and targeted therapeutic pathways.

Keywords: adaptive immunity; atherosclerosis; immunological targets; immunotherapy; innate immunity.

Publication types

Review

Grants and funding

This study was supported by the National Natural Science Foundation of China (No. 81960663), Hainan Medical College Basic Medical Audit Key Laboratory Open Subject Fund Project (No. JCKF2021001), Natural Science Foundation of Hainan Province Youth Project (No. 821QN401), Youth Incubation Fund of the First Affiliated Hospital of Hainan Medical College (No. 494 HYYFYPY202006). Hainan Province Health and Health Industry Research Project (No.21A200344).